References
- Willis S G, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137
- Thomas J, Wang L, Clark R E, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745
- Steinbach D, Legrand O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia 2007; 21: 1172–1176
- Wang D S, Kusuhara H, Kato Y, Jonker J W, Schinkel A H, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003; 63: 844–848
- Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark R E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258–264
- White D L, Saunders V A, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 Activity: higher doses of imatinib may overcome the negative impact of low OCT-1 Activity. Blood 2007; 110: 4064–4072
- Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005; 27: 634–640
- Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M A, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496–3499
- Larson R A, Druker B J, Guilhot F, O'Brien S G, Krahnke T, Gathmann I, et al. Imatinib plasma concentration and Sokal risk score are independently prognostic for complete cytogenetic response (CCyR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). Blood (Suppl.) 2007; 110: 1935
- Giannoudis A, Davies A, Lucas C M, Harris R J, Pirmohamed M, Clark R E. Unlike imatinib, dasatinib uptake into chronic myeloid leukaemia cells is independent of hOCT1 expression. Blood (Suppl.) 2007; 110: 3458
- Hiwase D K, White D L, Saunders V A, Dang P, Venables A, Eadie L, et al. In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. Blood (Suppl.) 2007; 110: 1937
- Davies A, Giannoudis A, Lucas C M, Harris R J, Manley P W, Pirmohamed M, et al. Characterisation of nilotinib transport in chronic myeloid leukaemia cells. Blood (Suppl.) 2007; 110: 2364
- Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926–935